High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

Autor:	M. O. Beyne-rauzy, D. Vassilieff, Lionel Adès, Stéphane Cheze, Pierre Fenaux, Sophie Park, L. Voillat, Jean-François Bernard, F. Hamza, M.C. Quarre, Claude Gardin, Lionel Mannone, S. Vaultier, Laurence Legros, P. Agape, Francois Dreyfus, Stéphane Giraudier
Rok vydání:	2006
Předmět:	Male medicine.medical_specialty Darbepoetin alfa Anemia Injections Subcutaneous Phases of clinical research Lower risk Gastroenterology Drug Administration Schedule Risk Factors hemic and lymphatic diseases Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Erythropoiesis Risk factor Erythropoietin Aged Aged 80 and over business.industry Myelodysplastic syndromes Hematology Middle Aged medicine.disease Treatment Outcome International Prognostic Scoring System Myelodysplastic Syndromes Immunology Drug Therapy Combination Female business medicine.drug
Zdroj:	British Journal of Haematology. 133:513-519
ISSN:	1365-2141 0007-1048
DOI:	10.1111/j.1365-2141.2006.06070.x
Popis:	An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) with an endogenous erythropoietin (EPO) level
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a66898dbe902375370ee64a5ae783b https://doi.org/10.1111/j.1365-2141.2006.06070.x Zobrazit plný text záznamu Plný text